Pharmaceutical composition and its application, sterile container and kit

A technology for aseptic containers and compositions, applied in the directions of drug combinations, medical containers, infusion sets, etc., to achieve the effect of improving anti-tumor treatment effect and reducing side effects

Active Publication Date: 2021-05-18
JIANGSU KANION PHARMA CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, the response rate of cancer patients to PD-L1 monoclonal antibody is only about 20%

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition and its application, sterile container and kit
  • Pharmaceutical composition and its application, sterile container and kit
  • Pharmaceutical composition and its application, sterile container and kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] In order to prove that the present invention has a good curative effect, animal experiments verify the therapeutic effect of the combination of tanshinone IIA and PD-L1 on the mouse non-small cell lung cancer model as follows:

[0034] 1 material

[0035] 1.1 Cell culture

[0036]Lewis murine lung adenocarcinoma cells (LLC) were purchased from the Cell Culture Center of Chinese Academy of Medical Sciences (Cell Culture Center of Chinese Academy of Medical Sciences; CAMS; People's Republic of China, Beijing). 90% DMEM medium (Dulbecco's modified Eagle's medium, Gibco BRL, USA), 10% FBS fetal bovine serum (fetal bovine serum, Gibco BRL, USA), in 5% CO 2 , 95%O 2 cultured in a constant temperature and humidity incubator at 37°C. Replace the culture medium every 2 to 3 days or determine whether to pass passage according to the cell density.

[0037] 1.2 Experimental animals

[0038] Healthy SPF grade female C57BL / 6 mice were used, purchased from the Institute of Labora...

Embodiment 2

[0068] 1 material

[0069] 1.1 Experimental animals

[0070] Twelve female NOD / SCID mice (6-8 weeks, 18-22g) were purchased from the Institute of Laboratory Animal Science (Institute of Laboratory Animal Science) of CAMS, Beijing, People's Republic of China, and were subjected to 12 hours of light under pathogen-free conditions. / dark cycle feeding acclimation for one week. Food and water were given throughout the experiment. Lewis cells were trypsinized and resuspended in 10% calf serum (5×10 5 cells / mL) in DMEM medium, each mouse was subcutaneously injected with 0.1 mL of Lewis cell suspension in the armpit of the left forelimb for inoculation.

[0071] 1.2 Drugs

[0072] Monomer tanshinone IIA with a purity of >98% was purchased from Shanghai Yuanye Biotechnology Co., Ltd., and was first dissolved in 1% DMSO, and then dissolved in 0.9% saline.

[0073] 2 methods

[0074] Twelve NOD / SCID mice were randomly divided into 2 groups, 6 in each group. After grouping, each g...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition and its application, a sterile container and a kit. The pharmaceutical composition includes a therapeutically effective amount of Tanshinone IIA and a therapeutically effective amount of at least one immune checkpoint inhibitor. The pharmaceutical composition improves the anti-tumor therapeutic effect of the immune checkpoint inhibitor on lung cancer and reduces side effects at the same time.

Description

technical field [0001] The present invention generally relates to the field of medicine, in particular to a pharmaceutical composition and its application, aseptic container and kit. Background technique [0002] Cancer is one of the major diseases that seriously endanger human health. Overcoming cancer has always been a research topic attracting worldwide attention. According to the survey of the World Health Organization, cancer patients are increasing year by year. Cancer is already one of the four major killers that seriously affect human health. It is characterized by uncontrollable growth and spread of malignant cells, as well as tissue infiltration. According to the "Classification of Diseases and Causes of Death" published by the Ministry of Health, it belongs to the diseases listed as malignant tumors. Currently, in addition to surgery, chemotherapy, and radiation therapy, which are the standard treatments for cancer, cancer immunotherapy has been developed as a ne...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K31/58A61P35/00A61M5/178A61J1/10
CPCA61J1/10A61K31/58A61K45/06A61M5/178A61P35/00A61K2300/00
Inventor 肖伟王永华郑春丽粟星姜梦王振中
Owner JIANGSU KANION PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap